2. Protein Tyrosine Kinase/RTK
  3. Btk
  4. (±)-Zanubrutinib

(±)-Zanubrutinib (Synonyms: (±)-BGB-3111)

Cat. No.: HY-101474 Purity: 99.70%
Handling Instructions

(±)-Zanubrutinib ((±)-BGB-3111) est un inhibiteur de tyrosine kinase de Bruton (Btk) qui est puissant, sélectif et oralement disponible.

(±)-Zanubrutinib ((±)-BGB-3111) is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor.

For research use only. We do not sell to patients.

(±)-Zanubrutinib Chemical Structure

(±)-Zanubrutinib Chemical Structure

CAS No. : 1633350-06-7

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply Now  
10 mM * 1 mL in DMSO USD 145 In-stock
Estimated Time of Arrival: December 31
5 mg USD 140 In-stock
Estimated Time of Arrival: December 31
10 mg USD 220 In-stock
Estimated Time of Arrival: December 31
50 mg USD 880 In-stock
Estimated Time of Arrival: December 31
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 4 publication(s) in Google Scholar

Other Forms of (±)-Zanubrutinib:

Top Publications Citing Use of Products

    (±)-Zanubrutinib purchased from MCE. Usage Cited in: Dr. Wang from Chinese Academy of Sciences.

    Determining IC50 for Zanubrutinib. IC50 values for Zanubrutinib are determined using the ADP-Glo™ Kinase Assay. Curve fitting is performed using GraphPad Prism sigmoidal dose-response (variable slope) software.

    (±)-Zanubrutinib purchased from MCE. Usage Cited in: Dr. Wang from Chinese Academy of Sciences.

    Determining IC50 for Zanubrutinib. IC50 values for Zanubrutinib are determined using the ADP-Glo™ Kinase Assay. Curve fitting is performed using GraphPad Prism sigmoidal dose-response (variable slope) software.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    (±)-Zanubrutinib ((±)-BGB-3111) is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor[1].

    In Vitro

    In both biochemical and cellular assays, (±)-Zanubrutinib ((±)-BGB-3111) demonstrates nanomolar Btk inhibition activity. In several MCL and DLBCL cell lines, (±)-Zanubrutinib inhibits BCR aggregation-triggered Btk autophosphorylation, blocks downstream PLC-γ2 signaling, and potently inhibits cell proliferation. In comparison with PCI-32765, (±)-Zanubrutinib shows much more restricted off-target activities against a panel of kinases, including ITK[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    In Vivo

    (±)-Zanubrutinib induces dose-dependent anti-tumor effects against REC-1 MCL xenografts engrafted either subcutaneously or systemically via tail vein injection in mice. In the subcutaneous xenografts. Preliminary 14-day toxicity study in rats shows that (±)-Zanubrutinib is very well tolerated and maximal tolerate dose (MTD) is not reached when it is dosed up to 250mg/kg/day[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Molecular Weight

    471.55

    Formula

    C₂₇H₂₉N₅O₃
    CAS No.

    1633350-06-7
    SMILES

    NC(C1=C2N(N=C1C3=CC=C(OC4=CC=CC=C4)C=C3)C(C5CCN(C(C=C)=O)CC5)CCN2)=O
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 30 mg/mL (63.62 mM)

    Ethanol : ≥ 10 mg/mL (21.21 mM)

    H2O : < 0.1 mg/mL (insoluble)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.1207 mL 10.6033 mL 21.2067 mL
    5 mM 0.4241 mL 2.1207 mL 4.2413 mL
    10 mM 0.2121 mL 1.0603 mL 2.1207 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.08 mg/mL (4.41 mM); Clear solution

    • 2.

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

      Solubility: 2.08 mg/mL (4.41 mM); Suspended solution; Need ultrasonic

    • 3.

      Add each solvent one by one:  10% DMSO    90% corn oil

      Solubility: ≥ 2.08 mg/mL (4.41 mM); Clear solution

    *All of the co-solvents are provided by MCE.
    References

    Purity: 99.70%

    COA (253 KB) HNMR (233 KB) LCMS (360 KB)

    Handling Instructions (2659 KB)
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Keywords:

    (±)-Zanubrutinib(±)-BGB-3111BtkBruton tyrosine kinaseInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email address *

    Phone number *

    		 

    Organization name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    (±)-Zanubrutinib
    Cat. No.:
    HY-101474
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email address *

    Phone number

    		 

    Department *

    Organization name *

    		 

    Country or Region *

    Remarks

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.